Lupus anticoagulants/antiphospholipid-protein antibodies: the great imposters.
Antiphospholipid-protein antibodies (APA) represent a family of immunoglobulins which recognize protein-phospholipid complexes. A variety of proteins have been implicated including: prothrombin, annexin V, beta 2-Glycoprotein I, and protein S. APA are detected utilizing either coagulation-based tests to identify lupus anticoagulants (LA) or solid phase ELISA assays to identify anticardiolipin antibodies (ACA). APA may be seen in a variety of different clinical settings including convalescence from infections, resulting from exposure to certain drugs, or in association with autoimmune diseases. Autoimmune APA have been linked to a variety of thromboembolic complications involving both arterial and venous sites. In addition, recurrent fetal loss has been linked to a APA. The underlying pathophysiology of the thromboembolic events remains controversial. Given the diversity of anatomic sites, more than one thromboembolic mechanism(s) is likely. Abnormalities of the protein C system most likely account for the venous thromboembolic events. Because of the spectrum of clinical complications, virtually any clinician may encounter patients with the APA syndrome (thrombosis, thrombocytopenia, recurrent fetal loss coupled with positive LA or ACA testing).
Triplett
D A
DA
Indiana University School of Medicine, Muncie, USA.
D017152:Antibodies, Antiphospholipid / Q000032:analysis*; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000032:analysis*; D013927:Thrombosis / Q000209:etiology
D017152:Antibodies, Antiphospholipid; D016682:Lupus Coagulation Inhibitor